# The Effect of Amantadine on Post-COVD-19 Fatigue

> **NCT05667077** · PHASE2 · UNKNOWN · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 83 (estimated)

## Conditions studied

- Post-COVID-19 Syndrome

## Interventions

- **DRUG:** Amantadine

## Key facts

- **NCT ID:** NCT05667077
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-26
- **Primary completion:** 2022-12-29
- **Final completion:** 2023-01-10
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2022-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05667077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05667077, "The Effect of Amantadine on Post-COVD-19 Fatigue". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05667077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*